Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 10:23 PM
Ignite Modification Date: 2025-12-24 @ 10:23 PM
NCT ID: NCT00766935
Eligibility Criteria: Inclusion Criteria: Groups 1 and 2 * Be female between the ages of 18-75 years. * Self-describe general health as satisfactory. * Understand the proposed study and be willing and fully able to comply with the study procedures. * Be a willing participant and be capable of giving and has given informed written consent for entry into the study. Group 1 * Have been previously diagnosed, by current clinical practice, as having unilateral Lymphoedema of the arm of any severity. * Have had a mastectomy or breast conservation surgery with axillary sampling or dissection, with or without adjuvant therapy. Exclusion Criteria: * Have a known heart condition or an implantable device such as a pacemaker or ICD. * Have a metallic surgical implant (e.g. total hip replacement) not including small implants such as sternal wires or surgical staples. * Suffer from a renal disorder. * Be taking diuretic medications. * Have consumed large amounts of alcohol or caffeinated beverages within six hours of the study. * Have undertaken excessive exercise within two hours of BIA. * Have a reported fever of \> 38oC at time of screening. * Be currently in the fourth week of the menstrual cycle. * Be pregnant or currently breastfeeding. * Be a relative of any member of study staff or is an employee or a relative of an employee of ImpediMed Ltd.
Healthy Volunteers: True
Sex: FEMALE
Minimum Age: 18 Years
Maximum Age: 75 Years
Study: NCT00766935
Study Brief:
Protocol Section: NCT00766935